Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 491 results found. Search for [ AstraZeneca COVID-19 vaccine trials ]

Results 1 to 21 of 491
Reuters
June 10, 2021
India has not granted indemnity to any COVID-19 vaccine maker, but the sources said the government was having a change of heart


Reuters
June 3, 2021
So far, only about 4.7% of the 950 million adult population have been given two vaccine doses as the world's second-most populous country reels from a devastating second wave of infections


Reuters
May 29, 2021
The decision comes after European Medicines Agency (EMA) backed the use of the vaccine in 12- to 15-year olds earlier in the day


PB Jayakumar
May 28, 2021
While official data shows 2.1 crore doses of Covaxin had been administered across the country till Thursday, based on statements from Bharat Biotech and Centre, at least 6 crore doses should have been produced and available for vaccination


BusinessToday.In
May 28, 2021
The MoU stated that Hester will provide complete infrastructure to manufacture the indigenously developed anti-COVID vaccine


Reuters
May 27, 2021
India has been inoculating its people with the AstraZeneca vaccine produced locally at the Serum Institute, Covaxin made by local firm Bharat Biotech, and has begun rolling out Russia's Sputnik V


BusinessToday.In
May 24, 2021
A guidance document on WHO website, updated last week, showed that Bharat Biotech submitted expression of interest for EUL on April 19.


BusinessToday.In
May 23, 2021
Efficacy against COVID-19-linked disease averaged around 85% after a full course, increasing to almost 100% protection against severe disease, hospitalisation or death, say University of Florida researchers


Reuters
May 22, 2021
India has not given any manufacturer of a COVID-19 vaccine indemnity against the costs of compensation for any severe side effects


PTI
May 21, 2021
The Centre will also take up with Moderna, Johnson and Johnson and other vaccine makers the issue of granting voluntary licence to third-party manufacturers in India on transfer of technology basis


Reuters
May 21, 2021
Moderna is the fourth COVID-19 vaccine to be approved in South Korea, following doses developed by AstraZeneca Plc , Pfizer Inc and Johnson & Johnson, said Kim


Reuters
May 20, 2021
Britain has suffered one of the worst death tolls globally from the pandemic, but has also had one of the fastest vaccine rollouts, generating a lot of data about the use of the shots in real world settings


PTI
May 18, 2021
The government last week extended the gap between two doses of the Covishield COVID-19 vaccine to 12-16 weeks, up from the previous maximum of eight weeks, on the recommendation of the NTAGI


PTI
May 18, 2021
During a daily virtual press briefing on Monday, the World Health Organisation Director-General said that the surge in COVID-19 cases around the world has compromised the global vaccine supply


BusinessToday.In
May 17, 2021
Govt committee has completed an in-depth case review of 498 serious and severe events, of which 26 cases were reported to have potential thromboembolic events. No such events were reported after administration of Covaxin vaccine


Shailendra Shukla
New Delhi, May 15, 2021
Extension of gap between Covishield doses 'reasonable approach', says Dr FauciAmid the furore over the extension of the gap between two doses of Covishield, White House chief medical adviser Dr Anthony Fauci said that it is a 'reasonable approach'. He said that if one is in a situation that India finds itself in currently, then one would have to try and figure out other ways to get as many as possible vaccinated. The comments come after the government announced on Thursday that the gap betwe...


Reuters
May 14, 2021
The Russian Direct Investment Fund (RDIF), which is responsible for marketing the vaccine abroad, said the manufacturing capacity for Sputnik V was increasing globally as new manufacturers come on board.


BusinessToday.In
May 13, 2021
Hyderabad-based Bharat Biotech had proposed to carry out a Phase-II/III clinical trial of Covaxin in the age group of 2 to 18 years. The trial will be conducted in 525 healthy volunteers


PTI
May 12, 2021
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur


PTI
May 9, 2021
Tata Sons President (Infrastructure, Defence, Aerospace and Global Corporate Affairs) Banmali Agrawala said people need to be vaccinated faster but safely as well


PAGES 1 OF 25  12345